Repository logo
Log in(current)
Repository logoMIT Open ScholarshipDSpace@MIT
  1. Home
  2. MIT Open Access Articles
  3. MIT Open Access Articles
  4. Dexamethasone: chondroprotective corticosteroid or catabolic killer?

Dexamethasone: chondroprotective corticosteroid or catabolic killer?

Thumbnail Image
Download
Name

v038a17.pdf

Description
Published version
Size

1 MB

Format

Adobe PDF

Checksum (MD5)

17780f12d490283f637c6ee148ddf4f4

sword-2020-03-06T18:48:40.original.xml (130 B)
Original SWORD entry document
Author(s)
Black, Robert Xavier
•
Grodzinsky, Alan J
Date Issued
November 2019
Journal
European Cells and Materials
Publisher
European Cells and Materials
Citation
Black, R. and A. J. Grodzinsky. "Dexamethasone: chondroprotective corticosteroid or catabolic killer?." European Cells and Materials 38 (November 2019): 246-263 © 2019 AO Research Institute Davos
Version
Final published version
Abstract
While glucocorticoids have been used for over 50 years to treat rheumatoid and osteoarthritis pain, the prescription of glucocorticoids remains controversial because of potentially harmful side effects at the molecular, cellular and tissue levels. One member of the glucocorticoid family, dexamethasone (DEX) has recently been demonstrated to rescue cartilage matrix loss and chondrocyte viability in animal studies and cartilage explant models of tissue injury and post-traumatic osteoarthritis, suggesting the possibility of DEX as a disease-modifying drug if used appropriately. However, the literature on the effects of DEX on cartilage reveals conflicting results on the drug’s safety, depending on the dose and duration of DEX exposure as well as the model system used. Overall, DEX has been shown to protect against arthritis-related changes in cartilage structure and function, including matrix loss, inflammation and cartilage viability. These beneficial effects are not always observed in model systems using initially healthy cartilage or isolated chondrocytes, where many studies have reported significant increases in chondrocyte apoptosis. It is crucially important to understand under what conditions DEX may be beneficial or harmful to cartilage and other joint tissues and to determine potential for safe use of this glucocorticoid in the clinic as a disease-modifying drug.
MIT Department
Massachusetts Institute of Technology. Department of Biological Engineering
Massachusetts Institute of Technology. Department of Mechanical Engineering
Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
http://creativecommons.org/licenses/by-nc-sa/4.0/
Persistent DSpace Link
https://hdl.handle.net/1721.1/126296
DOI of Published Version
https://doi.org/10.22203/ecm.v038a17
Repository logo
PrivacyPermissionsAccessibilityContact us
Repository logo
Notify us about copyright concerns.